Fingolimod

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released August 12, 2010; last updated August 10, 2017; expires August 10, 2020

Historical note and terminology

Fingolimod, first synthesized in 1992, is derived from myriocin, a metabolite of the fungus Isaria sinclairii, found to have immunosuppressive properties. Fingolimod belongs to a class of disease-modifying agents called sphingosine 1 phosphate (S1P) receptor modulators. It was originally tested in clinical trials on renal transplant patients but not found to be superior to the conventional immunosuppressant agents and, hence, not developed further for this indication. In 2010, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee recommended approval of fingolimod as an oral therapy for the treatment of patients with relapsing-remitting multiple sclerosis. It is now approved for this indication in the United States, Canada, the European Union, Russia, and Australia. It is one of the first orally active drug therapies to be made available for the treatment of relapsing-remitting multiple sclerosis.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.